Jim Cramer on Royalty Pharma: “It’s a Terrific Company”

Royalty Pharma plc (NASDAQ:RPRX) is one of the stocks Jim Cramer shared his take on. A caller asked for Cramer’s take on the stock, and here’s what he had to say:

Royalty just keeps going higher… I love that whole business where they help fund bio, and they get the returns. It’s a terrific company. I remember when GA brought it public, and I liked it then, I like it now.

Stock market data. Photo by Alesia Kozik on Pexels

Royalty Pharma plc (NASDAQ:RPRX) makes money by buying up royalties for multiple drugs and funding new research in the biotech world. Its current line-up includes a vast number of treatments from cancer to rare diseases. On January 11, the company announced that it had entered into a funding agreement with Teva Pharmaceuticals to accelerate the clinical development of TEV-‘408, an anti-IL-15 antibody targeting several autoimmune diseases. CEO and Chairman of the Board of Royalty Pharma plc (NASDAQ:RPRX), Pablo Legorreta, said:

Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.